1. Simulations Plus supports FDA's roadmap to reduce animal testing with NAMs. 2. This aligns with SLP's market offerings in biosimulation and cheminformatics.
SLP's support for FDA initiatives highlights its commitment to innovation. Historical examples show that companies aligned with regulatory trends often see positive market reception.
The article addresses regulatory support directly related to SLP's core business, enhancing its market appeal.
As regulatory frameworks evolve towards NAMs, SLP is positioned for sustained growth. Companies adopting innovative practices typically benefit over extended periods.